Principles of clinical management of ovarian cancer

Gorodnova, Tatiana V.; Sokolenko, Anna P.; Kuligina, E.; Berlev, Igor; Imyanitov, Evgeny N.

doi:10.21037/cco.2018.10.06

Cited by 28 publications

(31 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EOC has a high prevalence in China and ranks as one of the most relentless types of tumors disturbing the female reproductive tract [ 14 ]. Clinical reports based on several groups have suggested that the majority of EOC patients have achieved a favorable outcome due to the early diagnosis which possesses important abilities contributing to the systematic optimization of therapeutic schedules [ 15 , 16 ]. Despite the fact that several clinicopathological indexes have been applied to screen EOC patients, these factors have limited specificity and sensitivity, which require further improvements [ 17 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

Long Noncoding RNA LINC01554 as a Novel Biomarker for Diagnosis and Prognosis Prediction of Epithelial Ovarian Cancer

2021

View full text Add to dashboard Cite

Objective. This study was aimed at exploring the diagnostic and prognostic value of long noncoding RNA LINC01554 (LINC01554) in epithelial ovarian cancer (EOC) patients. Patients and Methods. The expressions of LINC01554 in 161 EOC patients were analyzed using RT-PCR. The area under the ROC curve (AUC) was used to estimate the effectiveness of LINC01554 for prediction. The chi-square test was performed to explore the association between LINC01554 expressions and clinical characteristics in EOC patients. Kaplan-Meier assays were conducted for the examination of the influence of LINC01554 expression on the overall survival of EOC patients. Multivariate analyses were carried out to further determine prognostic values of LINC01554 expression in EOC patients. Results. LINC01554 expressions were strongly downregulated in EOC specimens compared with matched nontumor specimens ( p < 0.01 ). Importantly, LINC01554 provided a high diagnostic performance for the detection of EOC specimens ( AUC = 0.7827 ; p < 0.001 ). Low expression of LINC01554 was distinctly associated with the FIGO stage ( p = 0.034 ) and distant metastasis ( p = 0.007 ). The assays of survival data (five years) revealed that the 5-year overall survival of the low LINC01554 expression group was distinctly shorter than that of the high LINC01554 expression group ( p = 0.0017 ). Finally, in the multivariate Cox model, LINC01554 expression ( RR = 2.863 , 95% CI: 1.185-4.421, p = 0.014 ) was demonstrated to be an independent prognostic factor for overall survival of EOC patients. Conclusions. Our findings suggested that LINC01554 is an important EOC-related lncRNA, providing a potential diagnostic, prognostic biomarker and therapeutic target for EOC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Long Noncoding RNA LINC01554 as a Novel Biomarker for Diagnosis and Prognosis Prediction of Epithelial Ovarian Cancer

2021

View full text Add to dashboard Cite

show abstract

“…They were told that all data concerning of self-sample would be handled with full confidentiality. 1,2,3,4,5,6 Yudi Mulyana Hidayat 1,2,3,4 Setiawan Soetopo 1,2,4 Sofie Rifayani Krisnadi 1,5,6 Maringan Diapari Lumban Tobing 1,5 Syahrul Rauf 1,4 Maringan ROC curve showing the value of combinantion GLS and CA-125 with Cytoreduction. AUC value was 85.4% CI 78.4%-92.3% (p = 0.0000), implicating that GLS can predict cytoreduction correctly in 91 patients out of a total of 109 patients.…”

Section: Methodsmentioning

confidence: 99%

“…The patients with epithelial ovarian cancer (EOC) who met the criteria will undergo primary cytoreduction, which is aimed to remove all visible tumors. [6] Patients with fewer residual tumors will have a better prognosis compared to the patients with more residual tumors after cytoreduction. [7] Cytoreduction surgery is a standard treatment for advanced stage epithelial ovarian cancer (EOC).…”

Section: [5]mentioning

confidence: 99%

The Combination of Serum Biomarker (CA-125, FASN, and GLS) as a Predictor Suboptimal Cytoreduction in Epithelial Ovarian Cancer

Winarno

Hidayat

Soetopo

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose. Cytoreduction has an important role in improving the survival rate of epithelial ovarian cancer (EOC) patients. The use of preoperative CA-125 as an optimal predictor cytoreduction in patients with ovarian cancer is still controversial. This study aimed to assess the ability of preoperative serum CA125, FASN and GLS as a predictor of cytoreductive surgery in epithelial ovarian cancer (EOC). This observational-analytic cross-sectional study included 109 women diagnosed with epithelial ovarian cancer (EOC) between 2017-2019, who had serum CA-125, GLS, FASN measured preoperatively and underwent cytoreductive surgery. Result. The average value of serum CA-125, FASN, and GLS in the suboptimal cytoreduction were higher than the optimal cytoreduction group. The cut off point (COP) of CA-125 was 248.55 (p=0.0001) with 73.2% sensitivity and 73.6% specificity, FASN was 0.445 (p=0.017) with 62.5% sensitivity and 60.4% specificity, and GLS was 22.895 (p=0.0001) with 73.2% sensitivity and 75.5% specificity. The COP value of CA-125 and GLS combined was 29.16 (p=0.0001) with sensitivity 82.1% and spesificity 73.6%, while the COP of CA-125, GLS, and FASN combined was 0.83 (p=0.0001) with 87.5% sensitivity and 73.6% specificity. If the value of biomarker serum more than COP will more likely have suboptimal cytoreductive surgery. Conclusion. The role of CA125, FASN and GLS levels in predicting suboptimal cytoreductive surgery for patients with ovarian cancer seems questionable. However, the combination of CA-125 and GLS or CA-125, FASN and GLS are able to increase the sensitivity, specificity, and accuracy classification to predict suboptimal cytoreductive surgery.

show abstract

“…(Jayson et al, 2014). Currently, primary debulking surgery, aimed to remove all visible tumor lumps, is a main treatment for EOC, yet, needs (Lin et al, 2011) chemotherapy before treatment because of wide metastasis and/or high risk of perioperative death (Gorodnova et al, 2018). Despite modern treatment, a large proportion of female in advanced EOC stage will develop recurrence within 18 months (Jayson et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Roles of metformin‐mediated girdin expression in metastasis of epithelial ovarian cancer

Dang

Gao

et al. 2021

Cell Biology International

View full text Add to dashboard Cite

Antimetastatic effect of Metformin has been documented in epithelial ovarian cancer (EOC). Presently, we investigated the regulatory mechanism of Metformin in EOC metastasis. First, Girdin was significantly enhanced in EOC tumorous tissues and cell lines. Seconded, knockdown of Girdin significantly suppressed EOC cell viability, migration, and invasion, while upregulation of Girdin produced the opposite effects in vitro and facilitated lung metastasis in EOC cell xenograft in vivo. In addition, we confirmed that the inhibitory effect of Metformin on Girdin expression. Mechanistically, the oncogenic effects of Girdin could be reversed by LY294002 (an AKT pathway inhibitor) and Metformin. These results suggested that Metformin attenuated EOC metastasis through Girdin and targeting Girdin may be a promising therapeutic strategy for EOC in the future.

show abstract

Principles of clinical management of ovarian cancer

Cited by 28 publications

References 3 publications

Long Noncoding RNA LINC01554 as a Novel Biomarker for Diagnosis and Prognosis Prediction of Epithelial Ovarian Cancer

Long Noncoding RNA LINC01554 as a Novel Biomarker for Diagnosis and Prognosis Prediction of Epithelial Ovarian Cancer

The Combination of Serum Biomarker (CA-125, FASN, and GLS) as a Predictor Suboptimal Cytoreduction in Epithelial Ovarian Cancer

Roles of metformin‐mediated girdin expression in metastasis of epithelial ovarian cancer

Contact Info

Product

Resources

About